Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Defibrotide Sodium

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Context Therapeutics Appoints Two New Board Members
    Context Therapeutics Appoints Two New Board Members

    04 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/04/2940408/0/en/Context-Therapeutics-Appoints-Dr-Karen-Smith-and-Dr-Luke-Walker-to-Board-of-Directors.html

    GLOBENEWSWIRE
    04 Sep 2024
    Share Share
    Jazz Pharma stops enrollment in phase 3 study evaluating defibrotide
    Jazz Pharma stops enrollment in phase 3 study evaluating defibrotide

    04 May 2020

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=123865&sid=2

    PHARMABIZ
    04 May 2020
    Share Share
    Jazz Stops Enrollment in Phase 3 Study Evaluating Defibrotide
    Jazz Stops Enrollment in Phase 3 Study Evaluating Defibrotide

    29 Apr 2020

    // PRESS RELEASE

    https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-stops-enrollment-phase-3-study-evaluating

    PRESS RELEASE
    29 Apr 2020
    Share Share